Is Januvia (Sitagliptin) Contraindicated with Sildenafil?
No, Januvia (sitagliptin) is not contraindicated with sildenafil. There is no documented drug interaction or contraindication between these two medications based on FDA labeling and current clinical evidence.
FDA-Labeled Contraindications
Sildenafil's only absolute contraindications are concomitant use with organic nitrates (in any form) and known hypersensitivity to sildenafil or its components—DPP-4 inhibitors like sitagliptin are not listed. 1
Sitagliptin (Januvia) has no listed contraindications in its FDA label that would preclude concurrent use with phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil. 2
Pharmacokinetic and Pharmacodynamic Considerations
Sitagliptin is primarily eliminated unchanged via renal excretion (approximately 79% unchanged in urine), with minimal metabolism by CYP3A4 and CYP2C8, making clinically significant cytochrome P450-mediated drug interactions unlikely. 2
Sildenafil does not affect glucose metabolism or insulin secretion, and sitagliptin does not influence phosphodiesterase-5 activity or vascular smooth muscle relaxation, so there is no overlapping mechanism that would create a pharmacodynamic interaction. 2, 1
The low plasma protein binding of sitagliptin (38%) further reduces the potential for displacement interactions with other highly protein-bound drugs. 2
Clinical Safety Profile
Sitagliptin has demonstrated cardiovascular safety in the TECOS trial (HR 1.00,95% CI 0.83–1.20 for heart failure hospitalization), with no increased risk of major adverse cardiovascular events, making it safe to use in patients who may also require PDE-5 inhibitors for erectile dysfunction or pulmonary hypertension. 3
Recent large-scale longitudinal data (509,788 men with erectile dysfunction) showed that sildenafil use was associated with reduced all-cause mortality (RR 0.76), myocardial infarction (RR 0.83), and stroke (RR 0.78), suggesting cardiovascular benefits rather than harm when used appropriately. 4
Important Clinical Caveats
The critical contraindication for sildenafil remains concurrent nitrate therapy (including nitroglycerin, isosorbide mononitrate, or isosorbide dinitrate), which can cause severe, potentially fatal hypotension—this restriction applies regardless of whether the patient is taking sitagliptin. 1
If a patient with type 2 diabetes on sitagliptin develops erectile dysfunction and requires sildenafil, ensure they are not taking nitrates and do not have severe cardiovascular instability; otherwise, sildenafil can be safely prescribed. 1, 4
For patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease with albuminuria who are considering glucose-lowering therapy, SGLT2 inhibitors or GLP-1 receptor agonists are preferred over sitagliptin due to proven mortality benefits, but this does not create a contraindication to sildenafil use. 3